Cardiorenal Benefits of GLP-1s Found in Type 1 Diabetes
A recent study found that GLP-1 receptor agonists (GLP-1RAs) can reduce the risk of major cardiovascular events and end-stage kidney disease in patients with type 1 diabetes. The research indicates that these benefits occur without increasing the risk of diabetic ketoacidosis or hypoglycemia. The findings suggest that similar therapeutic strategies used in type 2 diabetes could be beneficial for all patients with type 1 diabetes, warranting further investigation through randomized controlled trials.
- ▪GLP-1RAs lowered the risk for major adverse cardiovascular events by 15% and end-stage kidney disease by 19% in type 1 diabetes patients.
- ▪The study analyzed data from 174,678 individuals with type 1 diabetes, with 14,488 initiating GLP-1RAs over a median follow-up of 38 months.
- ▪No increased risks of hospitalizations for diabetic ketoacidosis or severe hypoglycemia were observed among GLP-1RA initiators.
Opening excerpt (first ~120 words) tap to expand
Adjunctive use of GLP-1 receptor agonists (GLP-1RAs) in patients with type 1 diabetes (T1D) lowered the risk for major adverse cardiovascular events (MACE) and for end-stage kidney disease (ESKD) without increased risks for either diabetic ketoacidosis (DKA) or hypoglycemia, new data from a target trial emulation showed. Current guidelines recommend GLP-1RAs for cardiovascular prevention in type 2 diabetes (T2D) regardless of A1c levels, and “our results support the consideration of similar therapeutic strategies for all patients with T1D, regardless of age or glycemic status,” wrote Yunwen Xu, PhD, of the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, and colleagues in their paper, published online as a brief communication in Nature Medicine.People with T1D have…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
